Capricor Therapeutics Inc (NASDAQ: CAPR) is having a great day in the market today after the company announced that a webinar will be coming soon. With a catalystic event just around the corner, excited investors are sending the stock screaming for the top. Today, we’ll talk about:
- The coming webinar;
- what we’re seeing from CAPR as a result; and
- what we’ll be watching for ahead.
CAPR Heads For The Top On Coming Webinar
As mentioned above, Capricor Therapeutics is having an incredibly strong start to the trading session this morning after announcing that a coming webinar will be coming soon. In a press release issued early this morning, the company announced that Parent Project Muscular Dystrophy (PPMD) will join it in hosting a webinar on July 18th at 1 pm ET.
During the webinar, CAPR said that it will be providing information on the HOPE-2 clinical trial. Through the trial, the company is assessing the safety and efficacy of repeat doses of CPA-1002 in boys and young men with Duchenne muscular dystrophy and reduced upper limb function.
In a previous clinical trial, known as HOPE-Duchenne, CAPR found that a single intracoronary dose of CAP-1002 in patients with advanced stages of DMD proved to be generally safe and well tolerated. Also, the study showed that the treatment led to significant and sustained improvement in cardiac and skeletal muscle function when compared to patients who received standard of care only. In a statement, Linda Marbán, Ph.D., CEO at CAPR, had the following to offer:
Please join PPMD and Capricor as we host this webinar to provide a brief background of CAP-1002 and its clinical development leading up to this exciting clinical trial… We will review the design of the HOPE-2 trial, eligibility criteria and assessments that participants will need to complete to participate in the trial.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news causes moves. In the case of Capricor Therapeutics, the news proved to be overwhelmingly positive. With the webinar around the corner, investors will be receiving news that is perceived to be positive surrounding what could become an overwhelmingly valuable product. So, it’s no surprise that excited investors are sending the stock screaming for the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (11:08), CAPR is trading at $1.49 per share after a gain of $0.11 per share or 8.14% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on CAPR. In particular, we’re interested in following the story surrounding CAP-1002 and excited to learn the new information that will be provided through the webinar on the 18th. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!